Liver Toxicity Is Wildcard In Xarelto Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Exanta’s failed application casts a 14-page shadow over J&J’s oral anticoagulant rivaroxaban.
You may also be interested in...
Xarelto Expanded Indication May Depend On Containing Worries About Bleeding
FDA advisory committee will review J&J/Bayer’s anticoagulant for a claim of reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome. The product has a profoundly stronger database, but the same set of safety concerns, compared to when it was initially approved.
J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability
J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability